Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic conditions, announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.
Two key presentations are scheduled: CFO Sylvia Cheung will deliver a corporate update available via webcast at 7:00 AM ET, while R&D President Snehal Shah will participate in a panel discussion on Pivotal-Stage Assets for Retinal Disorders from 11:00 AM to 12:00 PM ET. Both presentations will be accessible for replay through Oculis' website.
Oculis Holding AG (Nasdaq: OCS), azienda biofarmaceutica globale specializzata nelle patologie oftalmiche e neuro‑oftalmiche, ha annunciato la propria partecipazione alla 5ª Conferenza Annuale Virtuale di Oftalmologia H.C. Wainwright il 13 agosto 2025.
Sono previste due presentazioni principali: la CFO Sylvia Cheung terrà un aggiornamento aziendale disponibile via webcast alle 7:00 AM ET, mentre il Presidente R&S Snehal Shah parteciperà a una tavola rotonda sugli asset in fase pivotale per i disturbi retinici dalle 11:00 AM alle 12:00 PM ET. Entrambe le presentazioni saranno disponibili in replica sul sito web di Oculis.
Oculis Holding AG (Nasdaq: OCS), compañía biofarmacéutica global especializada en afecciones oftálmicas y neuro‑oftálmicas, anunció su participación en la 5.ª Conferencia Anual Virtual de Oftalmología de H.C. Wainwright el 13 de agosto de 2025.
Se han programado dos presentaciones clave: la CFO Sylvia Cheung ofrecerá una actualización corporativa mediante webcast a las 7:00 AM ET, mientras que el Presidente de I+D Snehal Shah participará en un panel sobre activos en fase pivotal para trastornos de la retina de 11:00 AM a 12:00 PM ET. Ambas presentaciones estarán disponibles en reproducción en el sitio web de Oculis.
Oculis Holding AG (Nasdaq: OCS), � 세계 안과 � 신경안과 질환� 전문으로 하는 바이오제약사� 오큘리스� 2025� 8� 13� 개최되는 H.C. Wainwright �5� 연례 안과 가� 컨퍼런스� 참가한다� 발표했습니다.
� 가지 주요 발표가 예정되어 있습니다: 최고재무책임�(CFO) Sylvia Cheung가 오전 7:00 AM ET� 기업 업데이트� 웹캐스트� 진행하고, 연구개발 책임� Snehal Shah� 오전 11:00 AM부� 12:00 PM ET까지 망막 질환� 위한 피보� 단계(pivotal‑stage) 자산� 관� 패널 토론� 참여합니�. � 발표 모두 오큘리스 웹사이트에서 다시보기� 제공됩니�.
Oculis Holding AG (Nasdaq: OCS), société biopharmaceutique mondiale spécialisée dans les affections ophtalmiques et neuro‑ophtalmiques, a annoncé sa participation à la 5e conférence annuelle virtuelle d'ophtalmologie H.C. Wainwright le 13 août 2025.
Deux présentations principales sont prévues : la directrice financière (CFO) Sylvia Cheung fera une mise à jour d'entreprise diffusée en webcast à 7:00 AM ET, tandis que le président R&D Snehal Shah participera à une table ronde sur les actifs en phase pivotale pour les troubles rétiniens de 11:00 AM à 12:00 PM ET. Les deux interventions seront disponibles en replay sur le site d'Oculis.
Oculis Holding AG (Nasdaq: OCS), ein globales Biopharmaunternehmen, das sich auf ophthalmologische und neuro‑ophthalmologische Erkrankungen spezialisiert hat, gab seine Teilnahme an der 5. jährlichen virtuellen Ophthalmologie‑Konferenz von H.C. Wainwright am 13. August 2025 bekannt.
Zwei Hauptpräsentationen sind geplant: CFO Sylvia Cheung wird um 7:00 AM ET ein Unternehmensupdate per Webcast geben, während Präsident Forschung & Entwicklung Snehal Shah von 11:00 AM bis 12:00 PM ET an einer Podiumsdiskussion über Pivotal‑Stage‑Assets für Netzhauterkrankungen teilnimmt. Beide Präsentationen werden auf der Website von Oculis zur Wiedergabe bereitgestellt.
- None.
- None.
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis�), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis� management will be participating in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.
- Sylvia Cheung, Oculis� Chief Financial Officer, will be presenting a corporate update which will be made available for replay via webcast at 7:00am ET.
- Snehal Shah, Oculis� President of R&D, will be participating in a live panel discussion from 11:00am to 12:00pm ET, on Pivotal-Stage Assets for Retinal Disorders. The panel discussion will also be made available via webcast for replay.
Links to access the corporate update presentation and the panel discussion will be posted to Oculis� website on the page under the Investors & Media section.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis� highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit:
Oculis Contacts
Ms. Sylvia Cheung, CFO
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
